Connecticut's medical cannabis program is about to get a lot bigger!

Last September the Regulation Review Committee approved two new conditions for the State's eight-year-old medical marijuana program. These recommendations were made by the Board of Physicians and Commissioner of Consumer Protection. By adding chronic pain and Ehlers-Danlos Syndrome to the list of qualifying conditions, there are now 38 ailments that qualify a patient for medical cannabis in the State of Connecticut. Below is a breakdown of approved conditions for adults over 18 years of age, as well as patients under the age of 18.

For Adults, Debilitating Medical Conditions Include:

• Cancer (Effective 2012)
• Glaucoma (Effective 2012)
• Positive status for HIV or Acquired Immune Deficiency Syndrome (Effective 2012)
• Parkinson's Disease (Effective 2012)
• Multiple Sclerosis (Effective 2012)
• Damage to the Nervous Tissue Of the Spinal Cord with Objective Neurological Indication of Intractable Spasticity (Effective 2012)
• Epilepsy (Effective 2012)
• Cachexia (Effective 2012)
• Wasting Syndrome (Effective 2012)
• Crohn's Disease (Effective 2012)
• Post-Traumatic Stress Disorder (Effective 2012)
• Sickle Cell Disease (Effective 2016)
• Post Laminectomy Syndrome with Chronic Radiculopathy (Effective 2016)
• Severe Psoriasis and Psoriatic Arthritis (Effective 2016)
• Amyotrophic Lateral Sclerosis (Effective 2016)
• Ulcerative Colitis (Effective 2016)
• Complex Regional Pain Syndrome, Type I and Type II (Effective 2016)
• Cerebral Palsy (Effective 2016)
• Cystic Fibrosis (Effective 2016)
• Irreversible Spinal Cord Injury with Objective Neurological Indication of Intractable Spasticity (Effective 2016)
• Terminal Illness Requiring End-Of-Life Care (Effective 2016)
• Uncontrolled Intractable Seizure Disorder (Effective 2016)
• Spasticity or Neuropathic Pain Associated with Fibromyalgia (Effective 2018)
• Severe Rheumatoid Arthritis (Effective 2018)
• Post Herpetic Neuralgia (Effective 2018)
• Hydrocephalus with Intractable Headache (Effective 2018)
• Intractable Headache Syndromes (Effective 2018)
• Neuropathic Facial Pain (Effective 2018)
• Muscular Dystrophy (Effective 2018)
• Osteogenesis Imperfecta (Effective 2018)
• Chronic Neuropathic Pain Associated with Degenerative Spinal Disorders (Effective 2018)
• Interstitial Cystitis (Effective 2019)
• MALS Syndrome (Median Arcuate Ligament Syndrome) (Effective 2019)
• Vulvodynia and Vulvar Burning (Effective 2019)
• Intractable Neuropathic Pain that is Unresponsive to Standard Medical Treatments (Effective 2019)
• Tourette Syndrome (Effective 2019)
• Ehlers-Danlos Syndrome (Effective 2020)

• Cerebral Palsy (Effective 2016)
• Cystic Fibrosis (Effective 2016)
• Irreversible Spinal Cord Injury with Objective Neurological Indication of Intractable Spasticity (Effective 2016)
• Severe Epilepsy (Effective 2016)
• Terminal Illness Requiring End-Of-Life Care (Effective 2016)
• Uncontrolled Intractable Seizure Disorder (Effective 2016)
• Muscular Dystrophy (Effective 2018)
• Osteogenesis Imperfecta (Effective 2018)
• Intractable Neuropathic Pain that is Unresponsive to Standard Medical Treatments (Effective 2018)
• Tourette Syndrome for patients who have failed standard medical treatment (Effective 2019)
• Ehlers-Danlos Syndrome